

BCL-2 is a highly sensitive and specific marker for thymomas with a type A component, effectively distinguishing them from type B-component thymomas. Differential BCL-2 expression intensity aids in separating thymomas from thymic carcinomas (including TSCT and MNTC). BCL-2 should be included in the routine IHC panel for TET subtyping.